Lapatinib and capecitabine efficacy at systemic and encephalic level in a patient progressed after dual block of HER2 by trastuzumab and pertuzumab and after T-DM1
Efficacia di lapatinib e capecitabina a livello sistemico ed encefalico in una paziente progredita al doppio blocco di HER2 con trastuzumab e pertuzumab e a T-DM1
DOI:
https://doi.org/10.19156/abtpn.2018.0039Keywords:
Lapatinib, Dual block, T-DM1, Metastatic breast cancer, Brain metastasisAbstract
We report the case of a patient with a stage IV ab initio HR-/HER2 positive breast cancer. The patient, treated with pertuzumab and trastuzumab for approximately 8 months, developed a progression of both systemic and cerebral disease. Subsequent treatment with T-DM1 obtained disease control for about 10 months. Afterwards we suggested a therapy based on lapatinib and capecitabine with a clear lasting response at encephalic level. This clinical case suggests that the combination of lapatinib + capecitabine is a valid option in case of double-block progression of HER2 and T-DM1. The interesting activity of lapatinib at encephalic level indicates the drug as one of the best therapeutic options available today in this patient setting (Oncology)
Downloads
Downloads
Published
How to Cite
Issue
Section
License
Authors contributing to AboutOpen agree to publish their articles under the Creative Commons NonCommercial 4.0 International License (CC BY-NC 4.0), which allows third parties to copy and redistribute the material providing appropriate credit and a link to the license but does not allow to use the material for commercial purposes and to use the material if it has been remixed, transformed or built upon.